Calvarial and skull base metastases: expanding the clinical utility of Gamma Knife surgery

Abstract

ObjectTraditionally, the treatment of choice for patients with metastases to the calvaria or skull base has been conventional radiation therapy. Because patients with systemic malignancies are also at risk for intracranial metastases, the utility of Gamma Knife surgery (GKS) for these patients has been explored to reduce excess radiation exposure to the perilesional brain parenchyma. The purpose of this study was to report the efficacy of GKS for the treatment of calvarial metastases and skull base lesions.MethodsThe authors performed a retrospective chart review of 21 patients with at least 1 calvarial or skull base metastatic lesion treated with GKS during 2001–2013. For 7 calvarial lesions, a novel technique, in which a bolus was placed over the treatment site, was used. For determination of local control or disease progression, radiation therapy data were examined and posttreatment MR images and oncology records were reviewed. Survival times from the date of procedure were estimated by using Kaplan-Meier analyses.ResultsThe median patient age at treatment was 57 years (range 29–84 years). A total of 19 (90%) patients received treatment for single lesions, 1 patient received treatment for 3 lesions, and 1 patient received treatment for 4 lesions. The most common primary tumor was breast cancer (24% of patients). Per lesion, the median clinical and radiographic follow-up times were 10.3 months (range 0–71.9 months) and 7.1 months (range 0–61.3 months), respectively. Of the 26 lesions analyzed, 14 (54%) were located in calvarial bones and 12 (46%) were located in the skull base. The median lesion volume was 5.3 cm3 (range 0.3–55.6 cm3), and the median prescription margin dose was 15 Gy (range 13–24 Gy). The median overall survival time for all patients was 35.9 months, and the 1-year local control rate was 88.9% (95% CI 74.4%–100%). Local control rates did not differ between lesions treated with the bolus technique and those treated with traditional methods or between calvarial lesions and skull base lesions (p > 0.05). Of the 3 patients for whom local treatment failed, 1 patient received no further treatment and 2 patients responded to salvage chemotherapy. Subsequent brain parenchymal metastases developed in 2 patients, who then underwent GKS.ConclusionsGKS is an effective treatment modality for patients with metastases to the calvarial bones or skull base. For patients with superficial calvarial lesions, a novel approach with bolus application resulted in excellent rates of local control. GKS provides an effective therapeutic alternative to conventional radiation therapy and should be considered for patients at risk for calvarial metastases and brain parenchymal metastases.

Successful Treatment of Anal Canal Cancer Metastasis to the Cranial Bones: A Case Report and Literature Review

“…The treatment of choice was 3D conformal RT with conventional fractionation (2 Gy per fraction) up to 55 Gy (3,29). Clinical experience with other RT techniques, such as stereotactic RT, was only limited to a retrospective analysis of 14 calvarial bone lesions (33). A 201-source 60Cobalt gamma knife radiosurgery system was used.…”

Lung carcinoma presenting as a solitary, painless frontal bone lump

“…Frequent complications are pathological fractures and compression of the spinal cord 15. Management of these metastases can often be complex and demands a multidisciplinary approach: analgaesic, surgical and radiotherapy treatment 11. In many patients, current treatment is palliative and not curative.…”

Metastatic Renal Cell Carcinoma Mimicking Trigeminal Schwannoma in a Patient Presenting with Trigeminal Neuralgia

“…Only 0.2% of intracranial tumors found in the CPA are metastatic in origin. 1 10 RCCs have an 11% incidence of brain metastases representing ∼ 1,100 patients per year. 11 A literature search revealed nine case reports of metastatic RCC presenting within the skull base and five case reports presenting within the sinonasal cavity.…”

“…Because of the relative radioresistance of RCC to traditional fractionated radiation delivery, radiation therapy and/or radiosurgery in combination with resection and systemic chemotherapy are the current treatment algorithms. 3 10 11 18 19 20 Shuto et al demonstrated the effectiveness of GKS with a dose ≥ 20 Gy for the treatment of metastatic brain tumors from RCC < 3 cm in maximum diameter. 21 Additionally, adjuvant chemotherapeutic drugs targeting tyrosine kinase receptors such as sorafenib and sunitinib show promise as second-line agents for the treatment of metastatic RCC.…”